Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Next Previous
X
Search
Trial Profile

A Phase Ia, Multicenter, Double-Blind, Placebo-controlled Study to Evaluate the Safety of CYT-108 for the Therapy of Mild to Moderate Primary Osteoarthritis of the Knee

Status: Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Jan 2025

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CYT 108 (Primary)
  • Indications Osteoarthritis
  • Focus Adverse reactions; First in man; Pharmacodynamics
  • Sponsors Cytonics Corporation

    • Most Recent Events

    • 21 Jan 2025 According to Cytonics Corporation media release,first nine patients in this trial successfully completed the study.
    • 06 Sep 2024 Status changed from recruiting to active, no longer recruiting, according to Cytonics Corporation media release.
    • 06 Sep 2024 According to Cytonics Corporation media release, phase 1 enrollment has been completed in this trial, a month earlier than the recruitment forecast. The top-line results and IND filing are expected in second quarter of 2025. This

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top